자가면역질환 진단 시장 : 제품 유형별, 검사 유형별, 기술별, 검체 유형별, 적응증별, 최종 사용자별, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Autoimmune Disease Diagnostics Market is projected to grow by USD 10.30 billion at a CAGR of 7.45% by 2032.

Autoimmune disease diagnostics are moving from episodic, symptom-led testing to earlier, multi-marker, and longitudinal assessment across rheumatology, gastroenterology, endocrinology, neurology, nephrology, and dermatology. Demand is supported by the high clinical burden of autoimmune disorders, delayed diagnosis in conditions such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, type 1 diabetes, inflammatory bowel disease, and celiac disease, and the need to distinguish inflammatory, infectious, malignant, and genetic mimics.

The market is anchored by established technologies such as indirect immunofluorescence assays, ELISA, chemiluminescent immunoassays, complement testing, HLA typing, tissue transglutaminase testing, anti-cyclic citrullinated peptide testing, antinuclear antibody testing, extractable nuclear antigen panels, and disease-specific autoantibody panels. Adoption is increasingly shaped by multiplex immunoassays, laboratory automation, digital pathology, companion-style biomarker strategies, and data integration with electronic health records to improve diagnostic confidence and patient monitoring.

Transformative Shifts in the Diagnostic Landscape

The autoimmune disease diagnostics landscape is being reshaped by three structural shifts: earlier risk detection, higher-throughput laboratory platforms, and more specialized clinical decision support. Clinicians increasingly require tests that support differential diagnosis, disease activity monitoring, flare prediction, organ involvement assessment, and treatment stratification rather than single-point confirmation. This is especially relevant because many autoimmune diseases have overlapping symptoms and may require combined interpretation of serology, inflammatory markers, imaging, biopsy findings, and clinical history.

Regulatory and quality expectations are also changing. The European Union In Vitro Diagnostic Regulation has raised requirements for clinical evidence, post-market surveillance, performance documentation, and notified body review, while U.S. laboratories continue to navigate evolving oversight of laboratory-developed tests. These shifts favor manufacturers and laboratories with validated assays, traceable controls, harmonized reporting, scalable automation, and strong medical education programs that help reduce false positives, false negatives, and unnecessary downstream testing.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of autoimmune diagnostics by improving pattern recognition, workflow triage, and interpretation across complex datasets. AI-enabled image analysis can support antinuclear antibody immunofluorescence pattern classification, while machine learning models can integrate serology, inflammatory markers, genomics, medications, symptoms, imaging, pathology, and longitudinal clinical data to identify patients needing specialist referral or closer monitoring.

The cumulative impact is operational as well as clinical. AI can help laboratories reduce manual review burden, flag inconsistent results, prioritize high-risk samples, support reflex testing pathways, and strengthen quality management. Its strongest near-term value is expected in decision support and laboratory efficiency, provided models are clinically validated, bias-tested, explainable, cybersecurity-protected, and integrated into regulated diagnostic workflows with clinician oversight.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

In Asia-Pacific, autoimmune disease diagnostics benefit from expanding hospital networks, rising private diagnostics investment, and broad adoption of automated immunoassay platforms in China, India, Japan, South Korea, and Australia. Population scale, growing chronic disease awareness, medical tourism, and increasing specialist access support test utilization, although reimbursement variability, urban-rural access gaps, and uneven availability of subspecialty immunology services remain important constraints.

North America remains a high-value region because of advanced clinical laboratories, strong rheumatology and gastroenterology networks, broad use of molecular and multiplex testing, and active adoption of digital health and electronic health record integration. Europe is shaped by strong public health systems, CE-IVD requirements, clinical guideline adherence, and high standards for assay validation under the In Vitro Diagnostic Regulation. Latin America shows rising demand in Brazil and Mexico, supported by private laboratory chains, urban specialty care expansion, and growing awareness of autoimmune thyroid disease, rheumatoid arthritis, and celiac disease. The Middle East, particularly Gulf health systems, is investing in advanced hospital diagnostics, reference laboratories, and tertiary care infrastructure, while Africa's development is tied to reference laboratory capacity, infectious disease differential diagnosis, workforce training, and improved access to specialist testing in major urban centers.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are characterized by growing private hospital groups, expanding medical tourism, and increasing use of centralized reference laboratories, especially in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. This creates demand for scalable autoimmune serology, celiac disease testing, thyroid autoantibody testing, and connective tissue disease panels. The GCC benefits from government-backed healthcare modernization, tertiary hospital investment, population screening initiatives, and demand for imported advanced diagnostic platforms that support specialist care pathways.

The European Union is a critical regulatory and commercialization benchmark because IVDR compliance affects assay classification, clinical evidence, post-market surveillance, and market access timelines. BRICS countries create large-volume opportunities, led by China, India, and Brazil, but require pricing discipline, localization, reimbursement awareness, and strong distributor or laboratory partnerships. G7 markets lead in specialty diagnostics adoption, reimbursement sophistication, digital laboratory infrastructure, and clinical research, while NATO countries collectively support resilient supply chains, laboratory interoperability, cybersecurity readiness, and healthcare security priorities relevant to uninterrupted essential diagnostic testing.

Key Country Insights Across Major Autoimmune Diagnostics Markets

The United States leads in autoimmune disease diagnostics through high test utilization, advanced reference laboratories, FDA-cleared platforms, broad insurance-linked clinical pathways, and strong adoption of multiplex panels. Canada benefits from publicly funded care, centralized provincial laboratory models, and evidence-based utilization management, while Mexico's demand is supported by urban private diagnostics, expanding specialty clinics, and cross-border healthcare activity. Brazil is the leading Latin American opportunity due to its large population, specialty care presence, public-private laboratory networks, and rising demand for rheumatology, thyroid, and gastrointestinal autoimmune testing.

In Europe, the United Kingdom emphasizes National Health Service pathways, clinical governance, and evidence-based testing; Germany combines advanced laboratory infrastructure with strong reimbursement discipline and high automation; France, Italy, and Spain show steady demand for rheumatoid arthritis, celiac disease, autoimmune thyroid disease, systemic autoimmune rheumatic disease, and inflammatory bowel disease diagnostics; and Russia relies on major urban centers for advanced immunology testing and specialist referral. In Asia-Pacific, China and India offer scale and fast laboratory modernization supported by hospital expansion and private diagnostics growth, Japan and South Korea emphasize quality, automation, precision medicine, and standardized workflows, and Australia benefits from guideline-driven testing, robust specialist referral systems, and strong laboratory accreditation practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated assay portfolios that address high-burden conditions such as rheumatoid arthritis, lupus, celiac disease, autoimmune thyroid disease, inflammatory bowel disease, type 1 diabetes, antiphospholipid syndrome, and autoimmune liver disease. Portfolio strategy should combine established serology with multiplex, molecular, and digital interpretation capabilities that improve diagnostic specificity, support reflex testing, and reduce unnecessary repeat testing.

Companies should invest in evidence generation, health economics, laboratory workflow automation, payer-facing clinical utility data, and education for clinicians and laboratory professionals. Regional success will depend on IVDR readiness, U.S. regulatory preparedness, local reference ranges, quality-controlled distribution, reagent supply resilience, interoperability with laboratory information systems, and partnerships with hospitals, reference laboratories, academic centers, and digital health platforms.

Research Methodology

This executive summary applies a secondary research methodology using publicly available, verifiable sources, including regulatory guidance, peer-reviewed clinical literature, professional society recommendations, government health data, disease burden studies, reimbursement frameworks, laboratory accreditation standards, and public health reports. Insights are triangulated across clinical adoption, laboratory infrastructure, regulatory requirements, technology maturity, guideline relevance, and regional access patterns.

Market interpretation is based on evidence-linked indicators rather than unverified assumptions. Key inputs include diagnostic guideline relevance, assay validation requirements, automation adoption, patient access dynamics, specialist density, reimbursement environment, laboratory quality systems, and the role of reference laboratories in scaling autoimmune disease testing. No market sizing, market share, or forecasting assumptions are used in this analysis.

Conclusion

Autoimmune disease diagnostics are becoming more precise, automated, and data-integrated as healthcare systems seek earlier detection, better differential diagnosis, and improved disease monitoring. Established serology remains essential, but differentiation is shifting toward validated multiplex panels, AI-enabled interpretation, robust quality systems, standardized reporting, and evidence-based clinical utility.

Organizations that align innovation with regulatory compliance, affordability, laboratory efficiency, supply reliability, and physician confidence will be best positioned to advance clinical adoption. The strongest opportunities lie in markets where specialist access, reimbursement support, laboratory accreditation, and diagnostic infrastructure converge to support timely autoimmune disease diagnosis and long-term patient management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Autoimmune Disease Diagnostics Market, by Product

• 7.1. Assay Kits & Reagents
• 7.2. Instruments
  • 7.2.1. Immunoassay Analyzers
  • 7.2.2. Microplate Readers

8. Autoimmune Disease Diagnostics Market, by Test Type

• 8.1. Autoantibodies & Immunologic Test
  • 8.1.1. Antinuclear Antibodies
  • 8.1.2. Cyclic Citrullinated Peptide Antibodies
  • 8.1.3. Disease-Specific Autoantibodies
• 8.2. Genetic Testing
  • 8.2.1. Chromosomal Tests
  • 8.2.2. Molecular Tests
• 8.3. Imaging Tests
  • 8.3.1. Magnetic Resonance Imaging
  • 8.3.2. Positron Emission Tomography
  • 8.3.3. Ultrasound
• 8.4. Inflammatory Markers
  • 8.4.1. C-reactive protein
  • 8.4.2. Erythrocyte Sedimentation Rate

9. Autoimmune Disease Diagnostics Market, by Technology

• 9.1. Enzyme-Linked Immunosorbent Assay
• 9.2. Flow Cytometry
• 9.3. Immunofluorescence Assay
• 9.4. Multiplex Assays
• 9.5. Next-Generation Sequencing
• 9.6. Western Blotting

10. Autoimmune Disease Diagnostics Market, by Sample Type

• 10.1. Blood
• 10.2. Saliva
• 10.3. Urine

11. Autoimmune Disease Diagnostics Market, by Indication

• 11.1. Organ-Specific Autoimmune Disease Diagnostics
  • 11.1.1. Graves' Disease
  • 11.1.2. Hashimoto's Thyroiditis
  • 11.1.3. Multiple Sclerosis
  • 11.1.4. Type 1 Diabetes
• 11.2. Systemic Autoimmune Disease Diagnostics
  • 11.2.1. Rheumatoid Arthritis
  • 11.2.2. Systemic Lupus Erythematosus
  • 11.2.3. Systemic Sclerosis

12. Autoimmune Disease Diagnostics Market, by End User

• 12.1. Ambulatory Care Centers
• 12.2. Diagnostic Laboratories
• 12.3. Hospitals & Clinics
• 12.4. Research Institutions

13. Autoimmune Disease Diagnostics Market, by Distribution Channel

• 13.1. Offline Sales
• 13.2. Online Sales

14. Autoimmune Disease Diagnostics Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Autoimmune Disease Diagnostics Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Autoimmune Disease Diagnostics Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Abbott Laboratories
• 18.2. AbbVie Inc.
• 18.3. AESKU.GROUP GmbH & Co. KG
• 18.4. Autobio Diagnostics Co., Ltd.
• 18.5. Beckman Coulter, Inc. by Danaher Corporation
• 18.6. Becton, Dickinson and Company
• 18.7. Bio-Rad Laboratories, Inc.
• 18.8. BioAgilytix Labs, LLC
• 18.9. bioMerieux SA
• 18.10. BIOSYSTEMS S.A.
• 18.11. Boditech Med Inc.
• 18.12. Chengdu Maccura Biotechnology Co., Ltd.
• 18.13. DiaSorin S.p.A.
• 18.14. Exagen Inc.
• 18.15. F. Hoffmann-La Roche Ltd.
• 18.16. FUJIREBIO by H.U. Group company
• 18.17. GlaxoSmithKline plc
• 18.18. Grifols, S.A
• 18.19. Hemagen Diagnostics, Inc.
• 18.20. JSR Life Sciences, LLC
• 18.21. Labcorp Holdings Inc.
• 18.22. Medical & Biological Laboratories Co. Ltd
• 18.23. Medsource Ozone Biomedicals Pvt. Ltd.
• 18.24. Menarini Group
• 18.25. Merck KGaA
• 18.26. Progentec Diagnostics, Inc.
• 18.27. PROTIA. iNC.
• 18.28. Quest Diagnostics, Inc.
• 18.29. Revvity, Inc.
• 18.30. RSR Limited
• 18.31. SD Biosensor, INC.
• 18.32. Sebia S.A.
• 18.33. Shanghai Kehua Bio-Engineering Co., Ltd.
• 18.34. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 18.35. Shenzhen YHLO Biotech Co.,Ltd.
• 18.36. Siemens Healthineers AG
• 18.37. Svar Life Science AB
• 18.38. Takeda Pharmaceutical Company Limited
• 18.39. Thermo Fisher Scientific Inc.
• 18.40. Trinity Biotech PLC
• 18.41. Werfen Group